Bill > H1202

This bill establishes a special commission to investigate maximum allowable costs (MAC) lists, which are used by health insurers and pharmacy benefit managers (PBMs) to determine the maximum amount they will pay for specific prescription drugs. The 10-member commission will include representatives from various stakeholder groups, such as state officials (including the secretary of health and human services, legislative leaders, and minority leaders), health plans, pharmacists, healthcare providers, pharmaceutical companies, and PBMs. The commission will comprehensively examine current MAC list practices, focusing on how these lists are developed, their financial implications, and potential industry-wide standardization efforts. The goal is to increase transparency in the process of determining drug pricing limits. The commission is required to submit a detailed report with findings and potential legislative recommendations to key legislative committees within 180 days of the act's passage, providing a thorough review of MAC list practices and potential areas for reform in pharmaceutical pricing.

Business and Industry

https://malegislature.gov/Bills/194/H1202